Qiagen N.V. (QGEN)
| Previous close | 42.68 |
| Open | 43.39 |
| Bid | 43.44 x 800 |
| Ask | 43.47 x 900 |
| Day's range | 43.25 - 43.51 |
| 52-week range | 34.74 - 47.70 |
| Volume | |
| Avg. volume | 1,071,435 |
| Market cap | 9.597B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 28.46 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.28 (2.94%) |
| Ex-dividend date | 30 Jan 2024 |
| 1y target est | N/A |
- GlobeNewswire
QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inherited disease applications
QCI Secondary Analysis a cloud-based software directly integrated with QCI Interpret, enabling high-throughput secondary analysis of clinical next-generation sequencing data // New software advances precision medicine by enabling smaller and decentralized labs to adopt NGS testing with efficiency, consistency and confidence // Combination of QCI Secondary Analysis and QCI Interpret provide a secure and compliant environment for trusted and scalable bioinformatics workflows for oncology and inher
- GlobeNewswire
QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance
Q1 2024: Net sales of $459 million (-5% actual rates, -5% constant exchange rates, CER); diluted EPS of $0.36 and adjusted diluted EPS of $0.46 // Net sales at CER of $462 million ahead of outlook for at least $455 million CER and adj. diluted EPS of $0.47 CER ahead of $0.44 CER outlook // Excluding COVID-19 product groups, net sales decline 1% CER // Diagnostics sales +5% CER on double-digit CER growth in QuantiFERON and QIAstat‑Dx // 25.7% adjusted operating income margin on efficiency gains v
- GlobeNewswire
QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and combat antimicrobial resistance
Launch of QIAseq xHYB Mycobacterium tuberculosis Panel for research use, enabling culture-free whole genome sequencing from complex samples // Panel significantly accelerates TB outbreak tracking and supports detection and management of antimicrobial resistance, critical needs in TB surveillance and control // Building upon success of leading diagnostics test QuantiFERON-TB Gold Plus as QIAGEN extends portfolio for TB management and control amid globally rising incidence ratesVenlo, the Netherla
